Liquidia Corporation

14.74
-0.35 (-2.32%)
At close: Mar 31, 2025, 3:59 PM
14.72
-0.11%
After-hours: Mar 31, 2025, 07:30 PM EDT
-2.32%
Bid 14.66
Market Cap 1.26B
Revenue (ttm) 15.17M
Net Income (ttm) -141.31M
EPS (ttm) -1.66
PE Ratio (ttm) -8.88
Forward PE -11.24
Analyst Buy
Ask 14.82
Volume 715,112
Avg. Volume (20D) 888,667
Open 14.82
Previous Close 15.09
Day's Range 14.41 - 14.97
52-Week Range 8.26 - 16.81
Beta 0.07

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisvill...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 26, 2018
Employees 170
Stock Exchange NASDAQ
Ticker Symbol LQDA
Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for LQDA stock is "Buy." The 12-month stock price forecast is $27, which is an increase of 83.18% from the latest price.

Stock Forecasts

Next Earnings Release

Liquidia Corporation is scheduled to release its earnings on May 12, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
+11.17%
Liquidia Corp shares are trading higher after the ... Unlock content with Pro Subscription
6 months ago
+14.04%
Liquidia shares are trading higher after the company announced it raised $67.5 million from the common stock financing of 6,460,674 shares at $8.90 per share.